Pharmabiz1d
EMA, HMA update principles for identification and disclosure of commercially confidential information & personal data
European Medicines Agency (EMA) and HMA (Heads of Medicines Agencies) have published a comprehensive overhaul of their guidance on the identification of commercially confidential information (CCI) and ...
Pharmabiz1d
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 gets EMA PRIME designation in relapsed extensive-stage small-cell lung cancer
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 gets EMA PRIME designation in relapsed extensive-stage small-cell lung cancer: London Saturday, December 21, 2024, 17:30 ...
Pharmabiz1d
Kenvue India presents evidence-based report on ‘The Hydration Gap for Non-Diarrheal Illnesses’
Kenvue, the world’s largest pure-play consumer health company by revenue, launches its latest evidence report on the role of fluids, electrolytes and energy (FEE) in non-diarrheal illnesses which ...
Pharmabiz1d
Samsung invests in Generate to advance AI-driven protein therapeutics discovery
Samsung invests in Generate to advance AI-driven protein therapeutics discovery: Incheon, South Korea Saturday, December 21, 2024, 17:00 Hrs [IST] Samsung announced that it has in ...
Pharmabiz1d
Neurizon submits IND application for its lead candidate, NUZ-001 with US FDA to support HEALEY ALS platform trial
Neurizon submits IND application for its lead candidate, NUZ-001 with US FDA to support HEALEY ALS platform trial: Melbourne, Australia Saturday, December 21, 2024, 16:00 Hrs [IST ...
Pharmabiz1d
Bioxodes enrolls patients in phase 2a clinical trial of BIOX-101 in intracerebral hemorrhagic stroke
Bioxodes enrolls patients in phase 2a clinical trial of BIOX-101 in intracerebral hemorrhagic stroke: Gosselies, Belgium Saturday, December 21, 2024, 15:00 Hrs [IST] Bioxodes SA, ...
Pharmabiz1d
Polyrizon inks manufacturing agreement for its PL-14 allergy blocker with Eurofins CDMO Amatsiaquitaine
Polyrizon inks manufacturing agreement for its PL-14 allergy blocker with Eurofins CDMO Amatsiaquitaine: Raanana, Israel Saturday, December 21, 2024, 14:00 Hrs [IST] Polyrizon Ltd ...
Pharmabiz1d
European Commission adopts positive opinion on Agios’ Mitapivat for orphan medicinal product designation in sickle cell disease
European Commission adopts positive opinion on Agios’ Mitapivat for orphan medicinal product designation in sickle cell disease: Cambridge, Mass Saturday, December 21, 2024, 12: ...
Pharmabiz1d
Fangzhou, Bristol Myers Squibb China ink collaboration agreement to advance internet healthcare solutions
Fangzhou, Bristol Myers Squibb China ink collaboration agreement to advance internet healthcare solutions: Shanghai Saturday, December 21, 2024, 11:00 Hrs [IST] Fangzhou Inc, a pi ...
Pharmabiz1d
Astellas signs license agreement with Sangamo Therapeutics to deliver genomic medicines for neurological diseases
Astellas signs license agreement with Sangamo Therapeutics to deliver genomic medicines for neurological diseases: Tokyo and Richmond, Calif Saturday, December 21, 2024, 10:00 Hrs ...
Pharmabiz1d
GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint
GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...
Pharmabiz1d
India should focus on critical, overlooked public health crisis posed by rare diseases: Prof. Ramaiah Muthyala
Nandita Vijayasimha, Bengaluru Saturday, December 21, 2024, 08:00 Hrs [IST] ...